Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Apellis Pharmaceuticals Inc (NQ: APLS ) 43.60 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, May 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 155 Open 43.60 Bid (Size) 42.00 (10) Ask (Size) 43.94 (1) Prev. Close 43.60 Today's Range 43.60 - 43.60 52wk Range 19.83 - 92.61 Shares Outstanding 116,457,008 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street May 14, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire In-Depth Examination Of 14 Analyst Recommendations For Apellis Pharmaceuticals May 08, 2024 Via Benzinga Performance YTD -28.84% -28.84% 1 Month -8.48% -8.48% 3 Month -34.82% -34.82% 6 Month -8.46% -8.46% 1 Year -51.34% -51.34% More News Read More APLS Stock Earnings: Apellis Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024 May 07, 2024 Via InvestorPlace Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results May 07, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Expert Ratings For Apellis Pharmaceuticals April 15, 2024 Via Benzinga If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,000 Today April 10, 2024 Via Benzinga $1000 Invested In This Stock 5 Years Ago Would Be Worth $3,000 Today March 29, 2024 Via Benzinga Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference May 06, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting May 01, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA) April 26, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Decoding 15 Analyst Evaluations For Apellis Pharmaceuticals March 27, 2024 Via Benzinga Peering Into Apellis Pharmaceuticals's Recent Short Interest March 15, 2024 Via Benzinga Deep Dive Into Apellis Pharmaceuticals Stock: Analyst Perspectives (18 Ratings) February 28, 2024 Via Benzinga Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results April 23, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire The 5 Stocks Most Sold By Insiders This Year April 16, 2024 Via MarketBeat Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 04, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Earnings Scheduled For February 27, 2024 February 27, 2024 Via Benzinga Here's How Much You Would Have Made Owning Apellis Pharmaceuticals Stock In The Last 5 Years February 22, 2024 Via Benzinga Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference April 01, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor March 11, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 06, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments March 06, 2024 Via MarketBeat ICU Medical To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Wednesday February 28, 2024 Via Benzinga Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results February 27, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Apellis Pharmaceuticals to Present at Upcoming Investor Conferences February 26, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
